Brean Murray Carret & Co. Maintains a 'Buy' on Halozyme Therapeutics (HALO); Oversold on HyQ News - Opportunity Heading Into Rituxan Phase 3
Go back to Brean Murray Carret & Co. Maintains a 'Buy' on Halozyme Therapeutics (HALO); Oversold on HyQ News - Opportunity Heading Into Rituxan Phase 3| Baxter International Inc. (NYSE: BAX) | Delayed: 26.34 -0.07 (0.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.41 | 52 Week High | $50.16 | |||
| Open | $26.51 | 52 Week Low | $34.06 | |||
| Day High | $26.67 | P/E | 7.20 | |||
| Day Low | $26.09 | EPS | $3.66 | |||
| Volume | 4,360,830 | |||||
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 108.17 +2.05 (1.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $106.12 | 52 Week High | $18.39 | |||
| Open | $106.20 | 52 Week Low | $6.96 | |||
| Day High | $108.49 | P/E | N/A | |||
| Day Low | $105.91 | EPS | $-0.58 | |||
| Volume | 1,173,974 | |||||
